New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
16:13 EDTDSCODiscovery Labs receives $30M investment from Deerfield
Deerfield Management announced that it has entered into a secured loan facility with Discovery Laboratories for up to $30M in financing. The financing provides Discovery with capital to commercialize its drug Surfaxin, which has been approved by the FDA for the prevention of Respiratory Distress Syndrome, or RDS, in premature infants at high risk for RDS, and its Afectair airway connector for infants receiving aerosolized medication in neonatal or pediatric intensive care units. The launch of these products will enable Discovery to transition from a development- to a commercial-stage company, and further develop its lead pipeline product, Aerosurf. The financing was structured to provide funding over time as needed and to avoid the dilution and potential discount of a public offering of stock or convertible debt financing. Under terms of the facility, Deerfield committed to advance $30M this year
News For DSCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 15, 2014
07:36 EDTDSCODiscovery Labs to collaborate with Battelle For Aerosurf program
Discovery Laboratories has entered into a strategic collaboration with Battelle, an independent research and development organization with 35 years of specific expertise in aerosol science. The parties intend to further develop Discovery Labs' proprietary capillary aerosol generator - or CAG - for use in the planned Aerosurf phase 3 clinical program and, if approved, initial commercialization. The CAG is currently being used in neonatal intensive care units for the company's Aerosurf phase 2 clinical program for the treatment of respiratory distress syndrome in premature infants. Battelle and Discovery Labs generally will share equally in the agreed costs of the device development for the Aerosurf RDS program. In consideration for its investment and expertise, Battelle will receive warrants and future royalties on AEROSURF sales and license sales revenues.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use